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Ways in which other transport systems may compensate for one that is genetically defective are 
considered. Comparisons of the transport systems of organelles (here the lysosome) with the transport 
system at the plasma membrane has significant implications for chemotherapy. 
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Some views have been held for many years that various cellular organelles, and 
even to some extent the cell itself, are surrounded by membranes somewhat 
porous to various hydrophilic metabolites. These molecules were supposed 
largely to diffuse through holes or non-specific aqueous channels, with only 
occasional and often inconsistent concern about what dimensions such pores must 
have to explain the supposedly free passage of a variety of hydrophilic molecules. 
Although not to be excluded entirely, such diffusive passage was held to occur, in 
the case of the plasma membrane, to degrees that at times seemed to me 
unproved, excessive and inconsistent, in superimposition to the more or less 
specific mediated transport otherwise under measurement. I had questioned a 
parallel explanation that held the cystine molecule slightly too large for diffusive 
passage to avoid its accumulation in the lysosomes of various cells in cystinosis. 
The opportunity to challenge this historic view of the mode of escape of amino 
acids from the lysosome came through a collaboration with Dr Jess G. Thoene, 
but only after decisive evidence had already been obtained by Gahl et al. (1) that 
the genetric defect in nephropathic cystinosis lies in the absence of a competent 
membrane transport carrier comparatively specific to cystine in the leucocyte 
lysosome. Through the competent hands of Dr Ronald Pisoni (2) failure of this 
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transport system was shown in my laboratory also to be accountable for cystine 
accumulation, in the same disease, in human skin fibroblasts. 
My subsequent interest has proceeded principally along the lines of the 
question whether the lysosomal membrane has an extensive set of such transport 
systems, in analogy to the set shown for the plasma membrane (3). Other 
organelles, including for example the hepatic mitochondrion and epithelial brush 
borders, have shown apparently different sets of such systems. We proceeded to 
characterize a system by which basic amino acids can be exchanged, one molecule 
for another, possibly a different but analogous one, across the fibroblast 
lysosomal membrane. This technique of looking for specific mediated exchange 
between two transport analogues across a biological membrane is widely but not 
universally available in the transport field. The pursuit of this problem has also 
been facilitated by the development of a method for selectively loading lysosomes 
with an amino acid supplied as its methyl ester, a procedure adapted to this 
purpose by Reeves (4). On the entry of this comparatively lipid-soluble derivative 
into the organelles, the esterase activity of the lysosome releases the free amino 
acid from its ester, leading to the trapping of the amino acid rather specifically in 
the lysosome, even in the presence of other contaminating organelles. In the 
present case the exodus of 14C-labeled lysine was shown to be accelerated by the 
external presence of unlabeled lysine through the transmembrane exchange of the 
two species. Similar experiments were made for exchanges between lysine and 
arginine, with one of these labeled, to further characterize the new transport 
system. This transport system for cationic amino acids proved equally functional 
in the normal and cystinotic lysosome (2). 
Gahl and other collaborating investigators have summarized recently (5) a 
broad study of the therapeutic value of administrating of cysteamine in cystinosis. 
The action of this monodecarboxylation product of cysteine was correctly 
attributed to its entry into a sulfhydryl-disulfide exchange reaction with the 
accumulated lysosomal cystine, a reaction which initially was incorrectly held to 
generate amino acid molecules small enough to escape via the hypothetical pores 
of that organelle. Our laboratory (2), again in the hands of Pisoni, proceeded to 
show that the critical therapeutic removal of cystine actually occurs instead in a 
modified form by the new transport system for basic amino acids. The mixed 
disulfide generated by the sulfhydryl-disulfide exchange, being itself a cationic 
amino acid, in effect a monodecarboxylation product this time of cystine, proved 
a substrate for the newly characterized system for transporting such amino acids 
Exodus of 14C-lysine could be shown to be stimulated by the external presence of 
the mixed disulfide of cysteine and cysteamine. Thus the therapeutic utility of 
cysteamine acquired a new explanation through its generation of a specifically 
transportable derivative of cystine. 
Our initial supposition was that the new transport system would be much like 
the one present in the plasma membrane of various cells, and also in the brush 
borders of epithelial tissues. This system we had designated y§ the plus sign 
serving to indicate its requirement for a net charge of plus one on the amino acid 
molecules ordinarily accepted by it. Some years later (6,7), however, we 
discovered, along with that feature, an unexpected further characteristic of this 
system in virtually every tissue tested that an accompanying sodium ion could 
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serve as a surrogate for the plus one charge on the sidechain of cationic amino 
acids. Hence certain dipolar ("neutral") amino acids could also be transported by 
system y+, leaving the plus sign perhaps somewhat ambiguous. 
At this point we were again surprised to discover that the new lysosomal 
system for basic amino acids showed no detectable corresponding reactivity with 
dipolar amino acids (8). Alpha-N-methyl arginine strongly inhibits [14C]arginine 
uptake by lysosomal system c in contrast to its lack of effect on system y+ in the 
plasma membrane. Furthermore, the distal N atom of lysine could be rendered 
quaternary (hence permanently cationic) by methylation, a change not acceptable 
to system y+. Gradually it became clear to us that the lysosomal system is quite 
unlike that of the plasma membrane (8). Indeed, if we selected an analog to 
cysteamine with quaternary N (namely thiocholine), we could produce with 
lysosomal cystine a reaction entirely analogous to that obtained with cysteamine, 
but with the possible advantage that the new mixed disulfide can pass the 
lysosomal membrane via the cationic amino acid system, without at the same time 
serving as an inhibitor for the approximately corresponding transport system of 
tl~e plasma membrane of the fibroblast. 
Thus our team has brought forth the concept of a novel therapeutic 
approach, setting up the service of a surviving transport system to carry out the 
function of one that is congenitally absent or defective (8). To explore this 
strategy fully, one needs to look also for any alternative route for the membrane 
transport, in this case of cystine per  se, that survives in the congenital defect, 
which might somehow be caused to serve effectively enough to compensate for 
the defect. For example, exposure to 43 ~ accelerates the subsequent loss of 
cystine, even from cystinotic fibroblast lysosomes, perhaps because an as yet 
unknown alternative system is intensified (Lemons et al., 8a). I have emphasized 
elsewhere (8b) the technology of kinetic challenges to the supposed homogeneity 
of any pertinent transport system, essential to the full description of the 
movement of a metabolite. 
Before extension to other transport defects, of the strategy of the use of a 
surviving transport system to substitute for a missing one, let me examine further 
a pertinent question: To what degree might various lysosomal transport systems 
prove different from those in the plasma membrane in ways that could prove 
biologically or therapeutically advantageous? 
So far our experiments had, as mentioned, been assisted by access to the 
measure of transport stimulation by the transmembrane exchange of transport 
analogs. This phenomenon had made it unnecessary to purify the lysosomes to a 
high degree. Now we needed to turn to transport systems that seemed not to 
show this phenomenon. To fill the resulting gap, Pisoni adapted the known 
technology of purifying lysosomes by Percoll gradient sedimentation. This 
technology allowed direct measure of the fluxes of various amino acids into or out 
of the organelle, although with more variance than one would wish. Incidentally, 
experience has taught that either of these opposed fluxes can prove useful for 
characterizing the transport facilities of a biomembrane. Three transport systems, 
e, f, and p, involved in the movements of such small dipolar amino acids as 
proline, alanine and the like were thus characterized by Pisoni et al. (9), as 
illustrated in Fig. 1. Subsequently, Collarini et al. characterized the mode of 
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Fig. 1. Provisional representation of the amino acid transport systems detected so far for human 
fibroblast lysosomes. In the FRTL cell line (25) the designation h may apply either to the component 
here marked t or to the total action of t + h. Sketch drawn by R. L. Pisoni as an extension of Fig. 9 in 
ref. 9. 
mediation of the transport of asparate and glutamate (10), which proved 
attributable to a single Na+-dependent system resembling system XAG of the 
plasma membrane (11, 12), although with further study clear differences again 
emerged. Several other systems participating along with this one in plasma 
membranes of various cells were not detected, however, for the lysosome. 
Our attention turned then, in the hands of Stewart et al. (13), to the mode of 
movement of the dipolar amino acids with bulky sidechains, for which the 
facilities in plasma membranes, namely systems L and T, are largely sodium-ion- 
independent and quite distinct. In the meantime, Bernar et al. (14) had partially 
characterized, under the designation lysosomal system h, the transport of 
L-tyrosine into a cultured thyroid cell line designated FRTL-5. A number of 
amino acids with bulky sidechains, including leucine and tryptophan, inhibited 
tyrosine uptake. Stewart soon obtained evidence that the competitive transport 
interactions with other bulky dipolar amino acids corresponded for the fibroblast 
lysosome to the participation of not one but at least two different transport 
systems, even though the total uptake both of phenylalanine and leucine 
correspond to a single rectangular hyperbola (13). At this point the situation 
seems to us reminiscent of that seen in human red blood cells, where system L 
serves for a large group of such amino acids, but a different system, T, prefers 
within this group the aromatic amino acids, tyrosine, phenylalanine, and 
tryptophan (see review, ref. 3). We seek model substrates specific to each of 
these systems to improve the evidence for a parallel situation in the lysosome. 
Although we began with a tendency to apply to the lysosomal systems the 
designations suggested by analogies of various strengths with the systems for 
plasma membranes, for example lysosomal systems y+, A, asc, etc., we soon 
came to see that these choices might bias our search for differences, as we tended 
to emphasize such manifestly imperfect analogies. The biological probability of 
their separate genetic determination, and also of their separate regulation, has led 
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Table 1. Search for parallelisms between somewhat analogous pairs of transport systems of plasma 
and lysosomal membranes 
Amino acids Plasma membrane sys tem Compared lysosomal Reasonably 
transported Designation (Na§ system analogous? 
Smaller dipolar No analog detected - -  Lysosomal system f9 
Proline, not ala Iminoglycine? Yes Lysosomal system p9 Dubious 
Small dipolar & 
small anionic ASC Yes Not detected 
Wide range of 
dipolar & cationic B ~ Yes Not detected 
Wide range of 
dipolar & cationic b ~ No Not detected 
Bulky dipolar L No Lysosomal system 112'14 Yes 
Aromatic T No Lysosomal system t 12 Yes 
or h 25 
Smaller dipolar asc No Lysosomal system e 9 Possibly 
Cystine, tetrapolar (E. coli) No Lysosomal cystine 
Cystine, glutamate x c No Not detected 
Glutamate, aspartate XA6 Yes Lysosomal system d 8 Yes 
Cationic (dipolar 
+ Na) y+ No Not detected 
Catonic (not. 
dipolar) Blastocyst 21 No Lysosomal system c 8 Yes 
us now to propose provisional designations that may instead go temporarily too 
far in ignoring the parallelisms between systems in the two types of membranes.  
As we look over our results at this stage (Table 1, above) we believe four or five 
of the parallelisms viewed post hoc are indeed considerable, although in no case 
do we conclude for identity of any pair of systems in the two membranes.  
Reconsideration of one or more provisional designations may come to be 
counseled by more striking parallelisms. Until the functional transport proteins 
have been sequenced, presumably with recognition of the complementary 
sequences in DNA,  are we likely to understand, through the recognition of 
homologies of structure, the differences and the parallelisms. I suspect that the 
general similarities and yet the differences in membrane transport functions 
among tissues and organelles at various degrees of differentiation will prove very 
interesting and important.  
The existence of these several lysosomal transport systems suggest that 
sulfhydryl compounds other  than aminothiols, e.g. mercaptoalkanes, 
mercaptoalkyl-sulfonates, or mercaptoalkyl carboxylic acids might be tested for 
their ability to stimulate exodus of cystine from lysosomes. Let  me return then to 
consider clues as to other  ways in which a surviving membrane transport system 
might be put into service in place of one congenitally deficient. Perhaps an earlier 
observation may suggest that supplementations between the service of epithelial 
transport systems assists our nutriture more often than we may realize. In 
Hartnup's  disorder the defect of a broad-range system serving in the epithelial 
absorption of various dipolar amino acids leads to urinary losses and retarded 
intestinal absorption of several such amino acids. The disorder can deserve the 
name disease only when the moderate  wastage of tryptophan it produces leads to 
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a pellegra-like dermatitis. Tests in a single subject with this disorder by 
phenylalanine and tryptophan feeding showed abnormally small responses in the 
rise of the circulating levels of these amino acids. If, however, glycyltryptophan 
or phenylalaninylphenylalanine were fed instead, much larger rises were pro- 
duced in the plasma levels of free tryptophan and phenylalanine (15). In these tests 
one of the known intestinal transport systems for dipeptides or oligopeptides was 
logically taken to serve in place of the defective system for free amino acids in 
Hartnup's disorder. Peptidase action in the epithelial cells usually, but not 
always, follows peptide absorption into these cells. Such nutritive substitutions of 
transport facilities might come into play spontaneously more often than we may 
realize, perhaps in some cases compensating for inborn transport defects that 
would otherwise be less benign than Hartnup's disorder (see 16). 
Recent evidence may suggest ways to enhance the service of a surviving 
transport system in compensation for that deficient in cystinuria, a disease of 
course dramatically unlike cystinosis. In the transport interactions defective in 
this disease, cystine is included among the diamino monocarboxylic acids; i.e., 
one of its carboxyl groups is apparently treated by the affected renal transport 
system as though it were received in the uncharged state (3). As I have already 
described for system y+, the two brush-border transport systems in question, 
namely the one congenitally absent in cystinuria and the one apparently serving in 
a varying degree of compensation, appear to be reactive also in the presence of 
sufficient levels of sodium ion with certain dipolar amino acids. This reactivity has 
also been described for the MDCK renal epithelial cell line (17). This effect had 
first been seen as a largely homoserine-dependent inhibition of homoarginine 
transport by Na § and by a Na § or Li§ inhibition of homoarginine 
uptake by homoserine or its 5-carbon homolog (7). The effect was subsequently 
extended to glutamine in experiments on human skin fibroblasts (18), although 
the shorter analog, serine, was always found relatively inactive. The interaction is 
also manifested by a trans-stimulated exchange across the plasma membrane of 
the monoamino acid plus sodium ion, on the one hand, for the diamino acid 
alone, on the other. Sodium ion inhibition did not, furthermore, fall to zero as 
the homoserine level was reduced to zero; i.e., sodium ion by itself inhibits 
arginine uptake (7). To secure the effect of the dipolar amino acids one needs a 
hydroxyl group or its terminal carbon 4 or 5, or a carboxamide group on carbon 
4. This spatial requirement points to a bonding to the sodium ion by otherwise 
unshared electrons of those two sidechain structures when they are at a suitable 
distance from the alpha carbon atom. 
An enhancement of the renal resorption of cystine in human cystinuria by 
the feeding of glutarnine has been investigated as a way to decrease the risk of 
renal stone formation, a recurrent problem in such patients. That effect is 
obtained, however, only when the sodium excretion is somewhat elevated (19). 
Indeed, sodium restriction alone may serve quite well by itself to reduce stone 
formation. I suggest, however, that administration of a selected amino acid may 
yet come to represent a helpful therapeutic aid in cystinuria, even when efforts 
have been made to decrease Na § intake, a possibility that should probably not be 
dismissed until the 4- and 5-carbon homologs of serine have been tried at readily 
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feasible decreases in sodium-ion excretion rates. Homoserine has been adminis- 
tered to human subjects at high dosages, sufficient indeed to produce evidence of 
ihemodilution, apparently without other significant unfavorable effects (20). The 
]hypothesis lying provisionally behind this suggestion is that such selected amino 
acids plus sodium ion may exchange for renal tubular cystine via a surviving 
brush-border transport system of the y§ type, to provide a significantly enhanced 
prophylaxis against stone in cystinuria. In the meantime, a watch should probably 
be kept for any more promising opportunities to apply the title strategy. 
The comparison obtained so far for lysosomal and plasma membrane systems 
is now concluded with reference to Table 1. The differences seen are somewhat as 
follows: Na+-dependence has not been seen with any of the lysosomal systems, 
but effects of an outward-directed Na§ have not yet been excluded. In 
that connection, system L uptake by fibroblasts seems to be enhanced by the 
~ntracellular presence of Na § along with an exchangeable amino acid (22). 
Lysosomal system f tolerates N-methylation of the amino group, whereas system 
e does not (9), a pattern reminiscent of the relation between systems A and either 
ASC or asc. Although variants of system A, as seen in transformed hepatocyte 
lines (23, 24), may ultimately need to be considered, parallelisms between 
lysosomal system f and plasma membrane systems for smaller dipolar amino acids 
are not yet impressive. For example, 2-aminoisobutyrate has little effect on 
proline uptake by lysosomal system f. Although lysosomal system e serves as the 
main route of passage of alanine, serine, and threonine, which three show 
mutually competitive uptake, that passage is scarcely affected by the presence of 
proline, or decreased by the lowering of the pH or replacement of Na § as seen 
for system ASC. Comparison of system e with Na+-independent system asc is 
more plausible than with ASC, but remains incomplete. 
The duality in the mediation of the membrane transport of bulky dipolar 
amino acids, by systems T and L in red blood cells, for example, and by systems t 
and 1 in the lysosomal membrane (13), as tested by the inhibition of a wide range 
of bulky aromatic and non-aromatic amino acids (cf. 14), may be emerging as an 
interesting parallelism, although model analogs are needed to enhance the 
precision of that discrimination in the lysosome. D-Tryptophan is the most 
effective inhibitor of the system by which L-tryptophan is preferentially taken up, 
while norleucine or BCH fully inhibits the saturable component of L-leucine 
lysosomal transport. If indeed two systems are involved here in the FRTL cell as 
well as in the fibroblast, the provisional designations t and I may prove more 
suitable than h (25). 
Cystine transport by the lysosomal membrane appears to call for recognition 
of all four of its potentially charged groups, a requirement not yet seen in higher 
animal plasma membranes, although cystine transport into E. coli appears to 
sJhow that feature (26). Otherwise cystine seems to be received as one or the 
other of the two plausible tripolar ions (3), e.g. as a glutamate analog by system 
XC. 
The system transporting aspartate and glutamate across the lysosomal 
membrane is similar to the ubiquitous system XAG (11), but differs clearly in 
these respects: (a) the stereoselectivity for the e isomers is weaker than in plasma 
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membranes, but as strong for one as for the other dicarboxylic amino acid; (b) 
3-aminoglutaric acid is a much weaker inhibitor of the lysosomal than for the 
plasma membrane system; (c) the N-methyl and omega-hydroxamate derivatives 
of aspartate and glutamate are inhibitory, the aspartate derivatives being the 
more effective, whereas in the plasma membrane only the aspartate derivatives are 
effective. In agreement with the indication of a longer space available for an 
anionic sidechain in the lysosome given by the hydroxamates, alpha-aminoadipic 
acid is a stronger inhibitor of the lysosomal than of the plasma membrane system; 
(d) as seen also for lysine in system c, methylation of the alpha amino group of 
aspartate or glutamate has little effect on their transport reactivity in both cases in 
the plasma membranes of various tissues. As recorded in Table 1, we no longer 
regard system c as a good analog of system y+, although substitution of a single 
amino acid residue in the transporter molecules might conceivably prove to 
account for the considerable difference in cationic amino acid transport observed 
between the two membranes. It seems rather likely to me that other tissues, e.g. 
the intestinal brush border or the preimplantation mouse blastocyst (21) may 
contain a closer analog of lysosomal system c with respect to its rejection of 
dipolar amino acids. 
In conclusion I urge that learning more about the specific transport functions of 
various cellular membranes may allow recognition of further congenital defects in 
these functions, and allow further opportunities for therapeutic use of an 
unimpaired transport system in substitution for the congenitally defective one. 
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